Patients treated with chemotherapy plus trastuzumab (Herceptin) had 92% iDFS with or without the bevacizumab. Subgroup analysis did not identify any group of patients that benefited from the addition of the angiogenesis inhibitor.
DRUG DEVELOPMENT DECONSTRUCTOR MANIFESTO: : “Tell me how you read and I'll tell you who you are.” ― Martin Heidegger
No comments:
Post a Comment